Spero Therapeutics shares rise on FDA approval

Although BMY shares experienced a 3.1% decline in the last close and the RSI at 32.7 is approaching oversold territory, the MACD line remains below the signal line. Trading below the 20- and 50-day moving averages indicates short-term weakness. While the news headline relates to Spero Therapeutics, there is no direct impact on BMY, and the current technical outlook maintains downward pressure. Therefore, the bearish trend is expected to continue in the near term.